TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting

NEW YORK, March 03, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that updated data for TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, has been selected for presentation at the upcoming 69^th American Academy of Neurology (AAN) annual meeting, to be held April 22-28, 2017, in Boston, MA.

Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, "We are very pleased to be able to present this early data from our Phase 2a study of TG-1101 in relapsing multiple sclerosis at the upcoming American Academy of Neurology annual meeting.  We believe B-cell depleting agents have the potential to transform the treatment of MS and believe TG-1101 is a highly active B-cell depleting agent that could offer patients a more convenient and cost effective treatment option.  As announced earlier this year, the doses tested have been well tolerated and we are extremely pleased with the rapid and profound B-cell depletion seen in the study.  We look forward to presenting these Phase 2 data, as well as commencing our Phase 3 study in MS in the coming months.”

The presentation details are as follows:

• Title: Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion
  - Abstract Number: 3113
  - Poster Presentation Number: 348
  - Session: Poster Session 6
  - Date and Time:  Friday, April 28, 2017 8:30 AM – 5:30 PM ET
  - Presenter: Amy E. Lovett-Racke, PhD, The Ohio State University, Columbus, OH

A copy of the above referenced abstract can be viewed online through the AAN meeting website at www.aan.com. Following each presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Statements included in this press release, particularly those with respect to anticipating the benefit of the early data seen in the Phase 2 MS trial, anticipating our ability to provide a cost effective treatment, our ability to provide a more convenient treatment option, as well as anticipating the timing of commencement of our MS Phase 3 program may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete the MS Phase 2 trial; the risk that early clinical results that supported our decision to move forward will not be reproduced in additional patients in expansion cohorts or in the MS Phase 3 program; the risk that the clinical results from the MS Phase 3 program, if conducted, will be not positive and/or will not support regulatory approval of TG-1101 for MS; our ability to successfully and cost-effectively complete the MS Phase 3 program; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission.  Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. 

TGTX - G

CONTACT:

Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]